Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02038348 : Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- B-RAF mutated metastatic melanoma.

- Reference imaging <1 month inclduing a whole body CT and 18F-FDG.

- At least one metastatic lesion at least with a diameter> 10 mm on CT.

- To which the staff has proposed, a B-RAF inhibitor in first-line treatment

- Signed informed consent.

Exclusion Criteria:

- Minor subject.

- Subject diabetic.

- Women of childbearing potential without effective contraception, with positive
pregnancy test.

- Other known active cancer.

- No affiliation to a social security (beneficiary or assignee).
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557